JP2016164156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016164156A5 JP2016164156A5 JP2016039991A JP2016039991A JP2016164156A5 JP 2016164156 A5 JP2016164156 A5 JP 2016164156A5 JP 2016039991 A JP2016039991 A JP 2016039991A JP 2016039991 A JP2016039991 A JP 2016039991A JP 2016164156 A5 JP2016164156 A5 JP 2016164156A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogen
- immunogenic
- group
- adjuvant
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002163 immunogen Effects 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 11
- 230000000890 antigenic effect Effects 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
- 101710132601 Capsid protein Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 229940037003 alum Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000031814 IgA Vasculitis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12098908P | 2008-12-09 | 2008-12-09 | |
| US61/120,989 | 2008-12-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013167494A Division JP5964280B2 (ja) | 2008-12-09 | 2013-08-12 | ＩｇＥＣＨ３ペプチドワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016164156A JP2016164156A (ja) | 2016-09-08 |
| JP2016164156A5 true JP2016164156A5 (enExample) | 2016-10-20 |
Family
ID=42035836
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540292A Expired - Fee Related JP5209800B2 (ja) | 2008-12-09 | 2009-12-04 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2012175784A Expired - Fee Related JP5367137B2 (ja) | 2008-12-09 | 2012-08-08 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2013167494A Expired - Fee Related JP5964280B2 (ja) | 2008-12-09 | 2013-08-12 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2016039991A Pending JP2016164156A (ja) | 2008-12-09 | 2016-03-02 | ＩｇＥＣＨ３ペプチドワクチン |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540292A Expired - Fee Related JP5209800B2 (ja) | 2008-12-09 | 2009-12-04 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2012175784A Expired - Fee Related JP5367137B2 (ja) | 2008-12-09 | 2012-08-08 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2013167494A Expired - Fee Related JP5964280B2 (ja) | 2008-12-09 | 2013-08-12 | ＩｇＥＣＨ３ペプチドワクチン |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8298547B2 (enExample) |
| EP (2) | EP2865389A1 (enExample) |
| JP (4) | JP5209800B2 (enExample) |
| KR (3) | KR101644221B1 (enExample) |
| CN (1) | CN102245198B (enExample) |
| AR (1) | AR074505A1 (enExample) |
| AU (1) | AU2009325950B2 (enExample) |
| BR (1) | BRPI0922561A2 (enExample) |
| CA (1) | CA2744754A1 (enExample) |
| CO (1) | CO6561830A2 (enExample) |
| DK (1) | DK2376108T3 (enExample) |
| ES (1) | ES2622562T3 (enExample) |
| IL (1) | IL213029A0 (enExample) |
| MX (2) | MX2011006077A (enExample) |
| NZ (2) | NZ592977A (enExample) |
| PE (2) | PE20142330A1 (enExample) |
| RU (1) | RU2495049C2 (enExample) |
| SG (2) | SG10201400388QA (enExample) |
| TW (1) | TWI387463B (enExample) |
| WO (1) | WO2010067286A2 (enExample) |
| ZA (1) | ZA201104072B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2594591B1 (en) * | 2005-08-11 | 2018-06-06 | Arpi Matossian-Rogers | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
| US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
| CA2745096C (en) | 2008-12-09 | 2013-11-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| EP2471926A3 (en) | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
| EP2714907B1 (en) * | 2011-05-26 | 2016-06-15 | Intervet International B.V. | Immunostimulatory oligodeoxynucleotides |
| CN107513533A (zh) * | 2011-05-26 | 2017-12-26 | 英特维特国际股份有限公司 | 免疫刺激性寡脱氧核苷酸 |
| US9956276B2 (en) | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| JP5918851B2 (ja) * | 2012-06-18 | 2016-05-18 | 日本全薬工業株式会社 | ＩｇＥペプチドワクチン |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| RU2021100991A (ru) | 2014-07-10 | 2021-03-01 | Аффирис Аг | Вещества и способы для применения при предупреждении и/или лечении болезни гентингтона |
| EP3357507A4 (en) * | 2015-09-30 | 2019-05-29 | Shionogi & Co., Ltd | NUCLEIC ACID DERIVATIVE WITH IMMUNOSTIMULATING EFFECT |
| KR101876620B1 (ko) * | 2015-10-27 | 2018-07-09 | 대구한의대학교산학협력단 | 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법 |
| CN108697779B (zh) | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
| JP7041923B2 (ja) | 2016-03-03 | 2022-03-25 | 学校法人藤田学園 | 大豆アレルギーの抗原 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| SG11201908059YA (en) * | 2017-03-29 | 2019-10-30 | Shionogi & Co | Nucleic acid derivative having immunostimulatory activity |
| JP7549148B2 (ja) * | 2020-08-13 | 2024-09-10 | ナイベック カンパニー リミテッド | 細胞内の腫瘍誘発タンパク質をターゲットとする抗体又はその単一鎖可変断片と癌細胞透過性ペプチドの融合タンパク質及びその用途 |
| EP4213874A1 (en) | 2020-09-17 | 2023-07-26 | Neovacs | Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders |
| US20250205331A1 (en) * | 2022-03-28 | 2025-06-26 | The Regents Of The University Of California | Novel plant virus and bacteriophage vaccines |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2055131B (en) | 1978-09-29 | 1982-12-15 | Energy Secretary Of State For | Electrical power transmission in fluid wells |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| WO1983001451A1 (en) | 1981-10-23 | 1983-04-28 | Molecular Biosystems Inc | Oligonucleotide therapeutic agent and methods of making same |
| US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| JPS63225397A (ja) * | 1986-10-03 | 1988-09-20 | Dainippon Pharmaceut Co Ltd | 抗アレルギー作用を有する新規ペプチド |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| US5258289A (en) * | 1990-09-05 | 1993-11-02 | Davis Claude G | Method for the selecting of genes encoding catalytic antibodies |
| JPH06503821A (ja) | 1990-12-20 | 1994-04-28 | スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） | Ｂ型肝炎表面抗原に基づくワクチン |
| SE9102808L (sv) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| EP0817854A2 (en) | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| EP0885244B2 (en) | 1996-03-01 | 2008-04-16 | Novartis AG | Peptide immunogens for vaccination against and treatment of allergy |
| ID18046A (id) | 1996-08-20 | 1998-02-19 | Takeda Chemical Industries Ltd | Senyawa siklik campuran, pembuatan dan penngunaannya. |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
| DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| ATE432348T1 (de) | 1997-06-06 | 2009-06-15 | Univ California | Inhibitoren von immunstimulatorischen dna sequenz aktivität |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| US6231864B1 (en) | 1998-02-12 | 2001-05-15 | Immune Complex Corporation | Strategically modified hepatitis B core proteins and their derivatives |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
| US7393529B2 (en) * | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
| US6734287B1 (en) * | 1998-04-09 | 2004-05-11 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
| ES2234180T3 (es) * | 1998-04-09 | 2005-06-16 | Idexx Laboratories, Inc. | Proteinas de fijacion especifica para el tratamiento de la alergia canina. |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| ATE434440T1 (de) | 1998-09-03 | 2009-07-15 | Novartis Vaccines & Diagnostic | Fgf-2 angiogenische wirksame einheitdosis und verfahren zu ihrer verwendung |
| DE59806475D1 (de) | 1998-09-18 | 2003-01-09 | Pentapharm Ag Basel | Urokinase-inhibitoren |
| CZ301212B6 (cs) | 1998-10-16 | 2009-12-09 | Smithkline Beecham Biologicals S. A. | Vakcinacní prostredek |
| AU770802B2 (en) | 1998-10-21 | 2004-03-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Virus-like particles for the induction of autoantibodies |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| ES2257879T3 (es) | 1998-11-05 | 2006-08-01 | Powderject Vaccines, Inc. | Productos de recombinacion de acido nucleico para inmunizacion genetica. |
| ES2317711T3 (es) | 1998-11-30 | 2009-04-16 | Cytos Biotechnology Ag | Presentacion molecular de alergenos, metodos de preparacion y uso. |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| EP1150710B1 (en) | 1999-02-17 | 2010-04-21 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US20030170229A1 (en) * | 1999-02-25 | 2003-09-11 | Smithkline Beecham Biologicals S.A. | Vaccine |
| CZ20013081A3 (cs) | 1999-02-25 | 2002-02-13 | Smithkline Beecham Biologicals S. A. | Epitopy a mimotopy získané z oblastí C-epsilon-2 nebo C-epsilon-4 IgE, jejich antagonisté a jejich terapeutické pouľití |
| EP1162999B1 (en) | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
| WO2000058365A1 (en) * | 1999-03-30 | 2000-10-05 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
| TR200103018T2 (tr) | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| JP2003509473A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| KR20020048942A (ko) | 1999-09-24 | 2002-06-24 | 장 스테판느 | 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트 |
| JP2003510290A (ja) | 1999-09-27 | 2003-03-18 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激核酸誘導インターフェロンに関する方法 |
| KR100808313B1 (ko) | 2000-04-07 | 2008-02-27 | 유니버시티 오브 리즈 이노베이션즈 리미티드 | 비형 간염 코어 항원 융합 단백질 |
| AU2001252458A1 (en) | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
| US20040054139A1 (en) | 2000-06-22 | 2004-03-18 | Mark Page | Modification of hepatitis b core antigen |
| EP1304947A1 (en) | 2000-07-15 | 2003-05-02 | Lighthouse Display International Limited | Shelf edge display fittings |
| AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
| US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| EP1195161A3 (en) * | 2000-08-30 | 2002-07-24 | Pfizer Products Inc. | Anti-IgE vaccines |
| GB0026334D0 (en) * | 2000-10-27 | 2000-12-13 | Smithkline Beecham Biolog | Vaccine |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| WO2003102165A2 (en) | 2002-02-21 | 2003-12-11 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
| GB0209878D0 (en) | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
| CU22983A1 (es) * | 2002-05-08 | 2004-09-09 | Inst Finlay | Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas |
| RU2324704C2 (ru) | 2002-07-17 | 2008-05-20 | Цитос Байотекнолоджи Аг | Молекулярные массивы антигенов |
| CN1838967B (zh) | 2002-12-10 | 2010-05-26 | 洛伦蒂斯有限公司 | 稳定的免疫原性HBc嵌合体颗粒 |
| JP5022028B2 (ja) * | 2003-03-26 | 2012-09-12 | サイトス・バイオテクノロジー・アクチェンゲゼルシャフト | メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート |
| CN102702359A (zh) | 2004-02-02 | 2012-10-03 | 泰勒公司 | 新的IgE表位的鉴别 |
| JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ， リミテッド | 先天免疫応答を誘導するための方法および組成物 |
| KR20100018029A (ko) | 2004-07-18 | 2010-02-16 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제 |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| GB2443591B (en) * | 2005-09-07 | 2010-04-28 | Secr Defence | Adjuvanted vaccine |
| EP1991678B2 (en) | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Compositions and methods for oligonucleotide formulations |
| US20080166785A1 (en) | 2006-08-16 | 2008-07-10 | Monica Sala-Schaeffer | Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use |
| US7867494B2 (en) | 2007-04-02 | 2011-01-11 | Amgen Fremont Inc. | Anti-IgE antibodies |
| EP2158211B1 (en) * | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
| US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
| ES2893464T3 (es) | 2016-06-23 | 2022-02-09 | Ripples Ltd | Procedimiento y aparato para imprimir en una bebida |
-
2009
- 2009-12-04 EP EP20140195370 patent/EP2865389A1/en not_active Withdrawn
- 2009-12-04 MX MX2011006077A patent/MX2011006077A/es active IP Right Grant
- 2009-12-04 BR BRPI0922561-7A patent/BRPI0922561A2/pt not_active IP Right Cessation
- 2009-12-04 ES ES09793590.2T patent/ES2622562T3/es active Active
- 2009-12-04 WO PCT/IB2009/055508 patent/WO2010067286A2/en not_active Ceased
- 2009-12-04 DK DK09793590.2T patent/DK2376108T3/en active
- 2009-12-04 KR KR1020137003578A patent/KR101644221B1/ko not_active Expired - Fee Related
- 2009-12-04 CA CA2744754A patent/CA2744754A1/en not_active Abandoned
- 2009-12-04 AU AU2009325950A patent/AU2009325950B2/en not_active Ceased
- 2009-12-04 KR KR1020117015895A patent/KR101413844B1/ko not_active Expired - Fee Related
- 2009-12-04 SG SG10201400388QA patent/SG10201400388QA/en unknown
- 2009-12-04 PE PE2014000753A patent/PE20142330A1/es not_active Application Discontinuation
- 2009-12-04 MX MX2013006964A patent/MX337723B/es unknown
- 2009-12-04 RU RU2011121043/10A patent/RU2495049C2/ru not_active IP Right Cessation
- 2009-12-04 CN CN200980149635.5A patent/CN102245198B/zh not_active Expired - Fee Related
- 2009-12-04 NZ NZ592977A patent/NZ592977A/xx not_active IP Right Cessation
- 2009-12-04 JP JP2011540292A patent/JP5209800B2/ja not_active Expired - Fee Related
- 2009-12-04 PE PE2011001186A patent/PE20110891A1/es not_active Application Discontinuation
- 2009-12-04 NZ NZ604186A patent/NZ604186A/en not_active IP Right Cessation
- 2009-12-04 EP EP09793590.2A patent/EP2376108B1/en not_active Not-in-force
- 2009-12-04 SG SG2012088373A patent/SG186611A1/en unknown
- 2009-12-04 KR KR1020157012347A patent/KR101634058B1/ko not_active Expired - Fee Related
- 2009-12-07 AR ARP090104737A patent/AR074505A1/es unknown
- 2009-12-08 TW TW098141914A patent/TWI387463B/zh not_active IP Right Cessation
- 2009-12-09 US US12/634,336 patent/US8298547B2/en not_active Expired - Fee Related
-
2011
- 2011-05-19 IL IL213029A patent/IL213029A0/en unknown
- 2011-06-01 ZA ZA2011/04072A patent/ZA201104072B/en unknown
- 2011-06-10 CO CO11072267A patent/CO6561830A2/es not_active Application Discontinuation
-
2012
- 2012-08-01 US US13/564,103 patent/US8475801B2/en not_active Expired - Fee Related
- 2012-08-08 JP JP2012175784A patent/JP5367137B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-29 US US13/904,432 patent/US9216229B2/en not_active Expired - Fee Related
- 2013-08-12 JP JP2013167494A patent/JP5964280B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-02 JP JP2016039991A patent/JP2016164156A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016164156A5 (enExample) | ||
| JP2012511322A5 (enExample) | ||
| Huang et al. | Escherichia coli-derived virus-like particles in vaccine development | |
| Thérien et al. | A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling | |
| JP2014507144A5 (ja) | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 | |
| JP2016509011A5 (enExample) | ||
| CN102711794B (zh) | 用于疫苗和诊断学的Dps融合蛋白 | |
| WO2011013034A4 (en) | Antigenic tau peptides and uses thereof | |
| JP2014502156A5 (enExample) | ||
| JP2009191078A5 (enExample) | ||
| JP2012501347A5 (enExample) | ||
| NZ592977A (en) | IgE CH3 PEPTIDE VACCINE | |
| JP2012501959A5 (enExample) | ||
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| JP2017538672A5 (enExample) | ||
| JP2013543499A5 (enExample) | ||
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| JP2015214545A5 (enExample) | ||
| JP2013541528A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| PE20140238A1 (es) | Metodos y composiciones para inmunoterapia para enfermedad neural | |
| JP2015505309A5 (enExample) | ||
| JP2010500398A5 (enExample) | ||
| JP2015504897A5 (enExample) | ||
| Chan et al. | Structure–activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates |